PAVmed Surges After Lucid Diagnostics Secures Key VA Contract for EsoGuard Cancer Test
Market Chameleon (Wed, 21-Jan 4:51 AM ET)
Market Chameleon (Wed, 21-Jan 3:19 AM ET)
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard
PRNewswire (Wed, 21-Jan 8:00 AM ET)
PAVmed Announces Reverse Stock Split
PRNewswire (Tue, 30-Dec 9:01 AM ET)
PRNewswire (Tue, 9-Dec 8:01 AM ET)
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
PRNewswire (Thu, 20-Nov 8:15 AM ET)
PRNewswire (Thu, 13-Nov 8:15 AM ET)
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
PRNewswire (Thu, 13-Nov 8:00 AM ET)
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
PRNewswire (Wed, 12-Nov 8:01 AM ET)
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
Pavmed trades on the NASDAQ stock market under the symbol PAVM.
As of February 2, 2026, PAVM stock price climbed to $8.70 with 1,033,390 million shares trading.
PAVM has a beta of 1.42, meaning it tends to be more sensitive to market movements. PAVM has a correlation of 0.09 to the broad based SPY ETF.
PAVM has a market cap of $8.02 million. This is considered a Sub-Micro Cap stock.
Last quarter Pavmed reported $5,000 in Revenue and -$.60 earnings per share. This fell short of revenue expectation by $-7,500 and exceeded earnings estimates by $5.40.
In the last 3 years, PAVM traded as high as $280.91 and as low as $6.00.
The top ETF exchange traded funds that PAVM belongs to (by Net Assets): VXF.
PAVM has underperformed the market in the last year with a return of -56.7%, while the SPY ETF gained +16.3%. In the last 3 month period, PAVM fell short of the market, returning -31.4%, while SPY returned +2.7%. However, in the most recent 2 weeks PAVM has outperformed the stock market by returning +32.2%, while SPY returned +0.7%.
PAVM support price is $6.93 and resistance is $8.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PAVM shares will trade within this expected range on the day.